RxDoctor Payments Data

Sonya Joubert

Family · Forest Hill, TXNPI 1942803754

Payments from drug & device makers

$702in general payments, 2019–2025

Across 19 payments — averaging $36.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$199
  • Otsuka America Pharmaceutical, Inc.$181
  • Dexcom, Inc.$150
  • Exact Sciences$35
  • Neurocrine Biosciences, Inc.$30
  • Merck$28
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$10,657
Medicare patients
83
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$27,376
MounjaroTirzepatide11$20,208
EliquisApixaban14$9,844
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,775
SynthroidLevothyroxine Sodium16$1,324
Albuterol Sulfate HfaAlbuterol Sulfate33$969
ValacyclovirValacyclovir Hcl14$933
Gabapentin35$921
Atorvastatin Calcium90$632
Levothyroxine Sodium42$539
Losartan Potassium46$536
Rosuvastatin Calcium34$448
Ezetimibe14$434
Quetiapine Fumarate16$393
Omeprazole28$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$199$27,37625 claims
Lilly USA, LLCMounjaro$20$20,20811 claims
PfizerEliquis$26$9,84414 claims
AbbVieSynthroid$19$1,32416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Forest Hill

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →